BNTX vs. TEVA: BioNTech vs. Teva Pharmaceutical Stock Comparison

Company Profile

BioNTech (BNTX) and Teva Pharmaceutical (TEVA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BNTX is classified in Biotechnology while TEVA is classified in Pharmaceuticals.

Both BioNTech (BNTX) and Teva Pharmaceutical (TEVA) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

BioNTech (BNTX) reports a negative ROE of -8.14%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Teva Pharmaceutical (TEVA) reports 6.65%, ranking against industry peers normally.

BioNTech (BNTX) reports a negative net margin of -60.87%, usually indicating a net loss over the period. Meanwhile Teva Pharmaceutical (TEVA) reports 2.94%, ranking against industry peers normally.

Both BioNTech (BNTX) at 30.28% and Teva Pharmaceutical (TEVA) at 27.40% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both BioNTech (BNTX) at 4.32% and Teva Pharmaceutical (TEVA) at 4.31% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Neither BioNTech (BNTX) nor Teva Pharmaceutical (TEVA) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

BioNTech (BNTX) at 8.55 keeps current ratio within its industry’s typical mid-range, while Teva Pharmaceutical (TEVA) at 0.95 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TEVA.

BioNTech (BNTX) at 0.02 keeps leverage in the lower quartile, while Teva Pharmaceutical (TEVA) at 2.13 is above its industry debt-to-equity ratio range.

Financial Strength Metrics

Dividends

Neither BioNTech (BNTX) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither BioNTech (BNTX) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Teva Pharmaceutical (TEVA) trades at 99.09 times trailing earnings, ranked against its peers, while BioNTech (BNTX) has no P/E ratio this period.

Teva Pharmaceutical (TEVA) at 2.89 sits in the cheaper P/S ratio quartile while BioNTech (BNTX) at 8.96 prices around its industry’s middle — TEVA costs less per dollar of sales, though read it alongside growth and margins.

BioNTech (BNTX) at 1.09 sits in the lower P/B ratio quartile against book while Teva Pharmaceutical (TEVA) at 6.23 is valued near its industry’s middle — BNTX is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics